There Is No Room for Allergy Fog This Spring Allergy Season with Claritin®

Leading Allergy Brand Taps Actor-Turned-Racecar Driver, Frankie Muniz, to Show Consumers that Allergies Do Not Need to Slow Them Down this Spring

WHIPPANY, N.J.--(BUSINESS WIRE)--This spring, leave allergy symptoms in the rearview! Today, Claritin®, the #1 doctor-recommend non-drowsy oral allergy OTC brand from Bayer, announced the launch of its new integrated creative campaign that shares there is no room for allergy fog, which is another way some consumers refer to their allergy symptoms. Claritin® provides powerful allergy relief. But, unlike some other OTC allergy relief medications, Claritin® is non-drowsy when taken as directed. To help drive awareness this allergy season, Claritin® has tapped actor-turned-racecar driver, Frankie Muniz, to encourage allergy sufferers to live life in the fast lane, whether on the speedway or on the road of life.

“As someone who has always suffered from seasonal allergies, it’s been critical that I find relief without the drowsy side effects,” said professional racecar driver and new Claritin® spokesperson, Frankie Muniz. “Whether chasing the finish line or my toddler son, there really is no room for allergy fog on any given day, so with non-drowsy Claritin® I live life to the fullest and keep the pedal to the metal.”

Just as allergy season revs up, Muniz will help allergy sufferers in New York City keep a foot on the gas this spring with a first-of-its-kind go-kart experience. Taking place at Pier 17 Seaport Square on April 19^th from noon to 2:00 PM ET, those who arrive on a first-come, first-served basis and show a valid driver’s license as well as sign a waiver will have the opportunity to drive the Claritin® Clear 500, a custom-built go-kart racetrack. Attendees will also have the opportunity to score product samples and other exciting giveaways to help them all allergy season long, while supplies last.

Consumers living outside of the NYC metro area will also have a chance to race toward relief. For a chance to win an all-expenses paid trip to see an upcoming professional race, consumers can take to Instagram to post a picture or video with the hashtags #ClaritinClear500 and #Sweepstakes as well as tagging @ClaritinUSA, including a brief description sharing why there is no room for allergy fog in their everyday lives. The sweepstakes will close for submissions on June 20. NO PURCHASE NECESSARY TO ENTER OR WIN IN THE “Claritin CLEAR 500” SWEEPSTAKES. Open to legal residents of the 48 contiguous US & DC, 18 or older. Void in AK, HI & where prohibited. Sweepstakes starts 4/17/23 and ends 6/20/23. For Official Rules, which govern, visit https://bit.ly/3ws37I1. Sponsor: Bayer HealthCare LLC.

“With the Claritin® family of products, allergy sufferers don’t need to trade efficacy for the drowsiness that some other allergy relief medications can cause,” said Catherine Vennat, a spokesperson for Claritin®. “Through our newest integrated campaign, we are hoping to wake up allergy sufferers to the fact that they don’t have to compromise and can Live Claritin Clear®.”

In addition to participating in the Claritin® Clear 500, Muniz will also be featured in branded content across social media, and the campaign will also be supported through digital and OOH.

For more information about Claritin® and the non-drowsy relief it provides, visit www.Claritin.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.